



23 September 2020

Company Announcements Office  
Australian Securities Exchange  
Exchange Centre  
20 Bridge Street  
Sydney, NSW 2000

## AUSTRALIAN PATENT GRANTED FOR NANOCELLE® DELIVERY PLATFORM

Medlab Clinical Ltd (ASX: MDC) is extremely pleased in the Australian granting of patent number 2016226280 described as “Transmucosal and transdermal delivery systems” providing protection until March 2036.


Dr Sean Hall, CEO of Medlab said, “This is the first patent granted for our NanoCelle® drug delivery platform, it is a huge validation of the science behind NanoCelle® and its innovative mode of action. NanoCelle® is used to greatly improve drug solubility issues resulting in improved absorption, metabolism and utilisation, giving us [Medlab] many options to improve prescription and over the counter medicines.”


“NanoCelle® is a key feature in our lead drug candidate NanaBis™ as well as in R&D programs of applying NanoCelle® to other known pharmaceutical ingredients giving us a robust pipeline of potential drug candidates that we can develop/commercialise.”

Medlab also has filed patent applications in the US, EU, NZ, SG, HK and Canada.

### About NanoCelle®:

- Validated by the NanoScale unit of Sydney University, Medlab’s NanoCelle® delivery system is an innovative process of creating nano-sized particles (certified to measure less than 100 nm), irrespective of their solubility characteristics (i.e., hydrophobic or hydrophilic nature) that render the molecular species with enhanced delivery properties via the oral-buccal or intranasal routes of administration.
- NanoCellisation produces nano-sized particles consisting of an inner hydrophobic core (active agents combined with lipid carrier or itself lipid-soluble) and an outer hydrophilic shell (various surfactants) and has an average particle size of from about 5 nm to approximately 90 nm (depending on cargo).





NanoCelle® results in better absorption of drugs avoiding ingested routes and can potentially allow lower dosage and reductions in side effects. NanoCelle® commercial applications will include:

- Providing patent extension on existing drugs from innovation in delivery technology
- Repurposing generic drugs and delivering innovation to differentiate
- Repurposing stronger, poorly absorbed drugs
- Cosmetics
- Food additives

**END**

#### **Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

#### **About Medlab – [www.medlab.co](http://www.medlab.co)**

Medlab Clinical Ltd is an Australian based biotechnology company, specialising in oncology related areas, such as pain management, quality of life and delivery platforms. Medlab holds multiple patents and is extensively published. Medlab's lead drug candidate is NanaBis™ targeting cancer bone pain.

For further information contact:

Dr Sean Hall, CEO Medlab Clinical Ltd

T: + 61 2 8203 9520 – [sean\\_hall@medlab.co](mailto:sean_hall@medlab.co)

Kyahn Williamson

WE Communications

T: + 61 0401018828 - [kwilliamson@we-worldwide.com](mailto:kwilliamson@we-worldwide.com)